Navigation Links
Zenobia Therapeutics, Inc. Receives Michael J. Fox Foundation for Parkinson's Research Award for Work on PD-implicated Protein LRRK2
Date:7/29/2008

for targeting neurological and psychiatric diseases."

Dr. Ross is a leader in neurodegenerative disease research; he helped to define LRRK2 as a PD target, and is an expert in its biology. As part of the collaboration, Zenobia will have access to cell assays and animal models developed by the Ross laboratory. "We are very excited to combine our expertise in fragment-based lead discovery with the expertise of Dr. Ross," said Vicki Nienaber, Ph.D., President and Founder of Zenobia. "We are a long way from a cure, but we took the first step this week with the help of the Michael J. Fox foundation."

Zenobia's research is focused on debilitating, limited-population diseases that have no cure. Zenobia combines fragment-based lead discovery with the expertise of biologists and clinicians to find treatments for illnesses such as Parkinson's disease, Huntington's disease and Muscular Dystrophy. In the future, Zenobia will focus on psychiatric diseases in parallel with increased understanding of the biology of these diseases.

For additional information on Zenobia Therapeutics, Inc., contact Dr. Vicki Nienaber at vicki@zenobiatherapeutics.com or visit http://www.zenobiatherapeutics.com.


'/>"/>
SOURCE Zenobia Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
2. Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase $44.5 Million of Units Consisting of Senior Convertible Notes and Warrants
3. Shareholders Approve All Matters Proposed by Cell Therapeutics, Inc. at Special Meeting in Lieu of Annual Meeting of Shareholders
4. Cell Therapeutics, Inc. Repays $11.0 million Balance of 2008 Convertible Debt
5. Cell Therapeutics, Inc. Special Meeting in Lieu of Annual Meeting of Shareholders Scheduled for Thursday, June 19, 2008
6. Cell Therapeutics, Inc. Announces Issuance of 2011 Convertible Senior Notes and Common Stock Warrants to a Single Institutional Investor
7. Anesiva and Transcription Factor Therapeutics, Inc. Announce Licensing Agreement for Development and Commercialization of NF-kappa B Clinical Program
8. Cell Therapeutics, Inc. (CTI) to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference
9. Vista Partners Initiates Coverage on Synvista Therapeutics, Inc. (AMEX: SYI)
10. Cell Therapeutics, Inc. (CTI) to Report 2008 First Quarter and Financial Results on May 8
11. Cell Therapeutics, Inc. Sells $64.5 million Units Consisting of Preferred Stock, New 2014 Convertible Senior Notes and Warrants to a Single Institutional Investor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... , May 28, 2015  PDS Biotechnology Corp. ... immunotherapy treatment targeting HPV-16, has generated strong T-cell ... Currently, pre-cervical cancer is treated by surgical removal ... and effective non-surgical alternative. Results show that it ... to recognize, target, and kill precancerous and cancerous ...
(Date:5/28/2015)... Biscayne Pharmaceuticals, Inc ., today announced ... hormone-releasing hormone (GHRH) technology will be discussed in a ... The data show that the family of receptors for ... present on many primary breast cancer cells regardless of ... could have broad anti-cancer potential in breast cancer. 1 ...
(Date:5/28/2015)... 28, 2015 CD-adapco, the largest ... software, announced today it is joining the consortium ... provide state-of-the-art engineering simulation tools for analyzing particle ... and experiences in analyzing particle flow that will ... advance the understanding of flow modeling solutions. , ...
(Date:5/28/2015)... Sunnyvale, Californiaa (PRWEB) May 28, 2015 ... on “ The Changing Landscape of EMR/EHR Clinical Data ... Annual Meeting taking place in Washington, DC on June ... the challenges of integrating EMR/EHR systems with EDC, and ... the opportunities brought by eSource and electronic health records/electronic ...
Breaking Biology Technology:PDS Biotechnology reports positive Phase I clinical trial results in proprietary HPV-Cancer Immunotherapy 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 3CD-adapco and PSRI Chartering New Course in Particle Flow Simulations 2Clinovo Presents at the DIA 2015 51st Annual Meeting in Washington, DC on June 14th-18th 2
(Date:5/19/2015)... , May 19, 2015  Technology is rapidly advancing, ... and in the cloud. Passwords and their management are ... OTP and standards-based specifications such as those developed by ... use of passwords presents for BYOD, COPE, IoT, and ... biometric identity protocol. In response to ...
(Date:5/11/2015)... May 11, 2015  Synaptics Incorporated (NASDAQ: ... solutions, today announced the appointment of Wajid ... Financial Officer, reporting to Rick Bergman , ... Chief Financial Officer, Kathleen Bayless , who ... Mr. Ali brings extensive financial management expertise ...
(Date:5/7/2015)... , May 7, 2015 ... sensors, FPC1022 and FPC1035, FPC,s smallest touch fingerprint ... are mainly considered for integration on the backside ... smartphone OEMs increased possibilities to integrate touch fingerprint ... size also improves possibilities for module manufacturers to ...
Breaking Biology News(10 mins):HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2
... F O R I M M E D ... A S E CELL TRANSPLANTATION,The Regenerative Medicine Journal Stem ... successfully treat animal models of lung disease Tampa, Fla. ... of Cell Transplantation (20:6), now freely available on-line at http://www.ingentaconnect.com/content/cog/ct/ , ...
... CHAMPAIGN, Ill. A new physics-based theory could give ... of liquids composed of large polymers. This advance provides ... fast-flow, high-stress processing conditions for plastics and other polymeric ... Margaret H. Professor of materials science and engineering at ...
... Bioinformatics Institute (VBI) at Virginia Tech will continue ... company Convey Computer as part of a new ... partnership will usher in a paradigm shift in ... Convey,s hybrid-core platform and relevant technologies," said Harold ...
Cached Biology News:Stem cells derived from human amniotic fluid hold promise 2Stem cells derived from human amniotic fluid hold promise 3New theory may shed light on dynamics of large-polymer liquids 2VBI, Convey Computer partner to deliver technology to biomedical, life sciences researchers 2
Mouse monoclonal antibody raised against a partial recombinant TPR. NCBI Entrez Gene ID = TPR...
... sufficient materials for 1,464 array sample elements. , , ... , Blocker BSA in PBS (10X): 50 ml , ... Saline: 8 packs , 10% Tween-20: 2 x 10 ... x 25 ml , SuperSignal West Pico Stable Peroxide: ...
... gun system, 100-120 V, is used for ... This handheld device employs an adjustable helium ... biomaterial-coated gold microcarriers from the inner wall ... target cells. This system has a 2 ...
... antibody raised against a partial ... Immunogen: ZFHX4 (NP_078997, 2 ... recombinant protein with GST tag. ... NM_024721 ...
Biology Products: